TROGARZO® RECEIVES POSITIVE RECOMMENDATION FROM SCIENTIFIC ADVISORY GROUP OF CHMP IN EUROPE
Scientific Advisory Group HIV/Viral Diseases (SAG), convened by the Committee for Medicinal Products for Human use (CHMP) in Europe, has given a positive recommendation to Trogarzo® (ibalizumab).
The meeting between the SAG and representatives from Theratechnologies took place this morning in Amsterdam, Netherlands.
A SAG is convened at the request of the CHMP to provide independent recommendations on scientific or technical matters relating to human immunodeficiency virus (HIV) and viral-disease products under evaluation by the CHMP, or on any other scientific issue relevant to the work of the CHMP that relates to this area.
The recommendation from the CHMP to the European Medicines Agency is expected to be announced around May 29, 2019